香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 自願公告 軒竹生物自研創新藥地羅阿克片獲國家藥監局上市批准 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為 「本集團」）董 事 會（「董事會」）欣 然 宣 佈，本 集 團 旗 下 非 全 資 附 屬 公 司 軒 竹 生 物 科 技 股 份 有 限 公 司（「軒竹生物」）自 主 研 發 的ALK抑制劑1類 創 新 藥 地 羅 阿 克 片（曾 用 名「達 希 替 尼」，XZP-3621，商 品 名：軒 菲 寧®）獲 得 中 國 國 家 藥 品 監 督 管 理 局 (NMPA)批 准 上 市，用 於 治 療 間 變 性 淋 巴 瘤 激 酶(ALK)陽性的晚期非小細胞肺癌 (NSCLC)。該產品是軒竹生物第三個獲批上市的1類 創 新 藥，同 時 也 是 軒 竹 生 物 第二個獲批上市的1類 ...

Core Viewpoint - The article discusses the recent developments in the GLP-1 drug market, particularly focusing on the approval and clinical trials of semaglutide for weight loss and diabetes management by Four Rings Pharmaceutical and its subsidiary Huisheng Biotech [2][4]. Company Overview - Four Rings Pharmaceutical is a comprehensive pharmaceutical company involved in research, production, sales, and medical aesthetics, evolving through four stages to establish a dual-engine model of "pharmaceuticals + medical aesthetics" [6]. - The company has a history of significant growth, with a compound annual growth rate (CAGR) that has outpaced the industry from 2001 to 2010, and has expanded its operations through acquisitions and upgrades [6]. - As of now, Four Rings has over 600 research personnel and more than 120 new drugs in development, with over 300 patents granted [7]. Product Development - Semaglutide, a new long-acting GLP-1 receptor agonist, has shown dual effects in lowering blood sugar and controlling weight by promoting insulin secretion and suppressing appetite [4]. - The "weight loss version" of semaglutide has completed its Phase III clinical trial enrollment and is now in the follow-up stage [2]. - The core component patent for semaglutide in China will expire in March 2026, with seven companies having their related applications accepted, focusing primarily on Type 2 diabetes treatments [5]. Market Competition - Novo Nordisk has been an early player in this market, with its diabetes injection product, Ozempic, approved in April 2021, followed by oral and weight loss versions in 2024 [5]. - The competitive landscape includes various companies pursuing different registration classifications and technical routes for semaglutide-related products [5].

格隆汇8月19日丨四环医药(00460.HK)宣布，本公司将于2025年8月29日（星期五）举行董事会会议，藉 以（其中包括）批准本公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布，并讨论及 通过（如适用）派发中期股息。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 董事會會議通知 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 八 月 二 十 九 日（星 期 五）舉 行 董 事 會 會 議，藉 以（其 中 包 括）批 准 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 中 期 業 績 及 其 發 佈， 並 討 論 及 通 過（如 適 用）派 發 中 期 股 息。 承董事會命 四環醫藥控股集團有限公司 主席兼執行董事 車馮升醫生 香 港，二 零 二 五 年 八 月 十 九 日 於 本 公 告 日 期，本 ...

Core Viewpoint - The stock price of Sihuan Pharmaceutical (00460) has decreased by 5.13% as of August 19, with a trading price of 1.48 CNY per share and a transaction volume of 96.40 million CNY [1]. Group 1: Company Overview - Sihuan Pharmaceutical Holdings Group Co., Ltd. is a leading pharmaceutical company in China's prescription drug market, primarily engaged in the production and sales of cardiovascular prescription drugs [1]. - Since 2007, the company has been the largest supplier of cardiovascular prescription drugs in the country [1]. - Key operational data includes a unique sales model, a nationwide sales network, a diversified product portfolio, and strong research and development capabilities [1]. Group 2: Financial Performance - As of the 2024 annual report, Sihuan Pharmaceutical reported total revenue of 1.901 billion CNY and a net profit of -217 million CNY [2].

消息面上，四环医药公布，集团旗下非全资附属公司惠升生物制药股份有限公司开发的司美格鲁肽注射 液上市申请获得国家药品监督管理局(NMPA)受理，用于改善成人2型糖尿病患者的血糖控制。此外，司 美格鲁肽注射液用于减重的适应症已完成III期临床入组，处于随访阶段。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇8月18日｜四环医药(0460.HK)盘中一度涨超10%，最高触及1.58港元，创2022年2月以来新高。 (责任编辑：宋政 HN002) 据悉，作为国内唯一在糖尿病及并发症领域实现全产品覆盖的生物医药企业，惠升生物的产品矩阵已形 成显著竞争力。除司美格鲁肽的几个在研管线外，公司已有近20款糖尿病及并发症药物获批上市，研发 管线的丰富性为其长期发展提供了坚实支撑。(格隆汇) ...

Core Viewpoint - Four Seasons Pharmaceutical (0460.HK) experienced a significant intraday increase of over 10%, reaching a peak of 1.58 HKD, marking the highest level since February 2022 [1] Group 1: Company Developments - The company announced that its non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd., has received acceptance for the market application of Semaglutide injection from the National Medical Products Administration (NMPA) for improving blood sugar control in adult patients with type 2 diabetes [1] - The clinical trial for Semaglutide injection's indication for weight loss has completed Phase III enrollment and is currently in the follow-up stage [1] Group 2: Competitive Position - Huisheng Biopharmaceutical is noted as the only biopharmaceutical company in China with a comprehensive product coverage in the diabetes and complications field, which enhances its competitive edge [1] - The company has nearly 20 approved diabetes and complications drugs in its product portfolio, and the richness of its research pipeline provides solid support for its long-term development [1]

智通财经获悉，四环医药(00460)涨超9%，截至发稿，涨7.69%，报1.54港元，成交额1.13亿港元。 消息面上，四环医药公布，集团旗下非全资附属公司惠升生物制药股份有限公司开发的司美格鲁肽注射 液上市申请获得国家药品监督管理局（NMPA）受理，用于改善成人2型糖尿病患者的血糖控制。此 外，司美格鲁肽注射液用于减重的适应症已完成III期临床入组，处于随访阶段。 据悉，糖尿病领域为惠升生物重点布局领域，本次司美格鲁肽注射液上市申请获国家药监局受理，是该 款药物研发进程中的又一重要进展，将有助于进一步提升集团和惠升生物在糖尿病治疗领域的核心竞争 力。 本文源自：智通财经网 ...

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Core Viewpoint - The significant surge of over 200% in the stock price of Sinovant Pharmaceuticals on its debut in the Hong Kong stock market is attributed to the market's high recognition of its first domestically produced long-acting GLP-1 receptor agonist and strong confidence in the vast potential of the weight loss drug market [1] Group 1: Market Dynamics and Company Performance - The stock price of Sihuan Pharmaceutical has increased nearly 150% this year, primarily driven by the high growth of its medical aesthetics business, indicating that the value of its innovative drug segment remains significantly underestimated [1] - The long-acting GLP-1 receptor agonist semaglutide, developed by Sihuan's subsidiary Huisheng Biopharma, has recently had its application for market approval accepted, with its Phase III clinical trial for weight loss now completed and in the follow-up stage, indicating imminent commercialization [3][4] Group 2: Product Advantages and Market Potential - Semaglutide's core advantages lie in its unique mechanism of action and clinical value, enhancing insulin secretion and suppressing glucagon secretion in a glucose-dependent manner, which has been recognized by global health authorities [5] - The drug's potential extends beyond glycemic control, as it can also reduce appetite and caloric intake, making it applicable in the treatment of metabolic diseases [5][6] Group 3: Industry Challenges and Opportunities - The global prevalence of diabetes and obesity presents significant challenges to public health, with the International Diabetes Federation projecting that the number of adults with diabetes will reach 589 million by 2024, and 853 million by 2050 [7][9] - Traditional therapies have limitations in managing these conditions, positioning GLP-1 therapies as a breakthrough direction in diabetes treatment and a key solution to metabolic disease challenges [9] Group 4: Competitive Positioning and Future Outlook - Huisheng Biopharma has established itself in the first tier of the industry, leveraging its first-mover advantage with semaglutide and other innovative products [11] - The company has built a comprehensive platform for diabetes treatment, with nearly 20 approved drugs and a robust pipeline, enhancing its competitive edge in the market [13] - Huisheng's integrated model of R&D, production, and sales ensures rapid market response and product quality, while its global partnerships are paving the way for international market expansion [15][16]